Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
liquid biopsy test
|
| gptkbp:analyzes |
circulating tumor DNA
|
| gptkbp:approvedBy |
advanced solid tumors
|
| gptkbp:CAPAccredited |
yes
|
| gptkbp:CLIACertified |
yes
|
| gptkbp:detects |
biomarkers
genomic alterations mutations in ALK mutations in BRAF mutations in EGFR mutations in ERBB2 mutations in KRAS mutations in MET mutations in NTRK mutations in PIK3CA mutations in RET mutations in ROS1 mutations in other cancer-related genes |
| gptkbp:developedBy |
gptkb:Guardant_Health
|
| gptkbp:enables |
detection of resistance mutations
monitoring of treatment response non-invasive tumor profiling personalized cancer therapy |
| gptkbp:FDAApproved |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Guardant360
|
| gptkbp:launched |
2014
|
| gptkbp:marketedIn |
gptkb:Asia
gptkb:Europe gptkb:United_States |
| gptkbp:parentCompany |
gptkb:Guardant_Health
|
| gptkbp:products |
gptkb:Guardant360_CDx
gptkb:GuardantOMNI gptkb:Guardant_Reveal |
| gptkbp:regulates |
CE marked
FDA approved |
| gptkbp:size |
over 70 genes
|
| gptkbp:technology |
next-generation sequencing
|
| gptkbp:turnaroundTime |
7 days
|
| gptkbp:type |
blood
|
| gptkbp:usedBy |
oncologists
pharmaceutical companies cancer researchers |
| gptkbp:usedFor |
cancer genomic profiling
companion diagnostics tumor mutation detection |
| gptkbp:website |
https://www.guardanthealth.com/guardant360/
|
| gptkbp:bfsParent |
gptkb:Guardant_Health
|
| gptkbp:bfsLayer |
6
|